MedPath Search

Found 539623 clinical trials

Sort by:

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

Not Applicable

Not yet recruiting

Conditions: Sepsis-induced Coagulopathy (SIC)

Interventions: Drug: Nafamostat Mesylate
Drug: sodium citrate

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 282

Registration Number: NCT06994312

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Biological: Tibulizumab Dose A
Biological: Tibulizumab Dose B
Other: Placebo

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Zura Bio Inc

Target Recruit Count: 180

Registration Number: NCT06993610

Locations: 🇺🇸
DelRicht LLC, Baton Rouge, Louisiana, United States

Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics in the Diagnosis and Prognosis of VAP

Not yet recruiting

Conditions: Ventilator Associated Pneumonia (VAP)

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Esraa Hamdy Thabit Riad

Target Recruit Count: 80

Registration Number: NCT06993623

Locations: 🇪🇬
Minia university Hospitals, Minya, Egypt

Retrieval-based Word Learning in Developmental Language Disorder: Adaptive Retrieval Schedule

Not Applicable

Recruiting

Conditions: Developmental Language Disorder
Specific Language Impairment
Language Development

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Purdue University

Target Recruit Count: 32

Registration Number: NCT06995014

Locations: 🇺🇸
Purdue University, West Lafayette, Indiana, United States

Glycemic Response to Carbob-Enriched Pasta in Healthy and With Type 1 Diabetes People

Not Applicable

Recruiting

Conditions: Glycemic and Insulinemic Response
Type 1 Diabetes (T1D)

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Federico II University

Target Recruit Count: 10

Registration Number: NCT06994403

Locations: 🇮🇹
Federico II University, Napoli, Italy

Increasing Screening for Cancer Using EHR-Nudges Replication

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7920

Registration Number: NCT06995703

Locations: 🇺🇸
Lancaster General Health, Lancaster, Pennsylvania, United States

Wearable Devices Faciliate the Management of AMI Patients

Recruiting

Conditions: Acute Myocardial Infarction

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: RenJi Hospital

Target Recruit Count: 400

Registration Number: NCT06995495

Locations: 🇨🇳
Renji Hospital, Shanghai, China

A Prospective, Multicenter, Controlled Clinical Study of 3D-printed Biodegradable Breast Implants for Breast Restoration

Phase 2

Recruiting

Conditions: Breast Cancer
Breast Reconstruction

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Xijing Hospital

Target Recruit Count: 120

Registration Number: NCT06993714

Locations: 🇨🇳
Xijing hospital, Xi'an, Shaanxi, China

Tirzepatide for Alcohol Use Disorder

Phase 2

Not yet recruiting

Conditions: Alcohol Use Disorder
Obesity and Overweight

Interventions: Drug: Tirzepatide
Drug: Placebo injections

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: University of Southern California

Target Recruit Count: 42

Registration Number: NCT06994338

Locations: 🇺🇸
Keck School of Medicine, University of Southern California, Los Angeles, California, United States

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Phase 2

Not yet recruiting

Conditions: Cancer-Associated Anorexia
Head and Neck Squamous Cell Carcinoma
Neck Squamous Cell Carcinoma of Unknown Primary

Interventions: Other: Best Practice
Other: Questionnaire Administration
Drug: Olanzapine

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 66

Registration Number: NCT06995508

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States